Article
Immunohistochemistry Profile Predicts EGFR Mutation Status in Lung Adenocarcinoma.
International journal of surgical pathology - 1 Aug 2020
Li Wencheng, Niehaus Angela G, O'Neill Stacey S
Abstract excerpt
Significant advances in targeted therapy have been made in recent years for patients with lung adenocarcinoma. These targeted therapies have made molecular testing of paramount importance to drive therapeutic decisions. Material for testing is often limited, particularly in cytology specimens and small core biopsies. A reliable screening tool is invaluable in triaging limited tissue and selection for epidermal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
